مقایسه‌ی اثرات درمانی دی‌فنیل‌سیکلوپروپنون موضعی با آنترالین موضعی در بیماری آلوپسی آره‌آتا پوست سر

Background: Alopecia areata is an autoimmune disease, as a non-scarring hair loss and is without clinical signs. Although spontaneous recovery occurs in many patients with alopecia areata, but a lot of patients suffer from chronic periods of the disease. And according to the related serious complications of corticosteroid treatment and high relapse rate, finding alternative effective treatment for these patients by dermatologists is still ongoing. Methods: 50 patients with alopecia areata scalp during the last 3 months, who had no response to treatment with corticosteroids, were enrolled in two equal groups. One group received therapy with topical Diphenylcyclopropenone (DPCP) and the other group was treated with topical Anthralin. (IRCT: 201410113566N5). Results: Patients in the two groups in terms of gender, age, extent and duration of the current period scalp disease were not significantly different. No significant difference was observed in treatment response between the two groups (P=0.189). Age, as the only prognostic factor in treatment DPCP was found (P=0.047) and any prognostic factor in Anthralin group not found. More complications was seen in Anthralin group compared to the DPCP group (P=0.018). The duration of treatment and relapse rate, there was no significant difference between the two treatment groups. Conclusion: Even better effect using DHCP in alopecia areata, but no significant difference Anthralin. But according to fewer side effects in DPCP and better effect on younger ages, this drug can be used as alternative treatment for resistant alopecia areata of children. [ABSTRACT FROM AUTHOR]